↓ Skip to main content

Access to and quality use of non-communicable diseases medicines in Nepal

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, August 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
73 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Access to and quality use of non-communicable diseases medicines in Nepal
Published in
Journal of Pharmaceutical Policy and Practice, August 2015
DOI 10.1186/s40545-015-0041-7
Pubmed ID
Authors

K.C. Bhuvan, Susan Heydon, Pauline Norris

Abstract

Noncommunicable diseases are a major healthcare problem in Nepal and their burden is increasingevery year. Noncommunicable diseases (NCDs) bring additional challenges to the Nepalese healthcaresystem which is already experiencing infrastructure shortages, poor service delivery, inadequate essential medicines coverage and shortages of healthcare workers. The Nepal government provides a limited number of free essential medicines through the free essential healthcare services program. This consists of a basic healthcare package provided through primary healthcare (PHC) facilities and district hospitals. Though around 40 essential medicines are provided without charge, studies have reported problems with access especially in all rural areas. There is a need to improve access to, coverage and quality use of medicines. The government has decided to provide some free medicines for NCDs alongside free essential medicines to be distributed via current healthcare structures. Though well intended, this decision will put extra strain on the essential medicines program. It should be supplemented by a comprehensive NCDs policy that takes account of the issues of sustainability and quality use of medicines. Complex cases of NCDs will be managed by tertiary hospitals but most of the cases of NCDs especially for rural people and the poor will end up in secondary level public hospitals (district and zonal hospitals). Therefore, the government needs to strengthen these public hospitals. Meanwhile, given the severity of the NCDs problem in Nepal, the Ministry of Health and Population (MoHP) should liaise with nongovernmental and missionary hospitals especially in rural areas to run NCDs management services. The Ministry should encourage these hospitals to run hospital pharmacies to improve people's access to and quality use of NCDs medicines. At the primary healthcare level, the Ministry could run NCDs prevention and control programs but existing PHC workers need training to perform proper dispensing of NCDs medicines. PHC facilities need a medical record system so that they can address the needs of NCDs patients requiring long term medication supply via a proximate PHC facility.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Nepal 1 1%
Unknown 72 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 20 27%
Researcher 9 12%
Student > Bachelor 6 8%
Other 5 7%
Student > Ph. D. Student 4 5%
Other 12 16%
Unknown 17 23%
Readers by discipline Count As %
Medicine and Dentistry 16 22%
Pharmacology, Toxicology and Pharmaceutical Science 9 12%
Nursing and Health Professions 8 11%
Social Sciences 8 11%
Agricultural and Biological Sciences 2 3%
Other 12 16%
Unknown 18 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2015.
All research outputs
#6,240,353
of 22,826,360 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#140
of 407 outputs
Outputs of similar age
#73,290
of 266,721 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#4
of 11 outputs
Altmetric has tracked 22,826,360 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 407 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,721 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.